

Global Hypertensive Heart Disease Drug Production, Demand and Key Producers, 2022-2028

<https://marketpublishers.com/r/GB4F2E26189AEN.html>

Date: December 2022

Pages: 119

Price: US\$ 4,480.00 (Single User License)

ID: GB4F2E26189AEN

Abstracts

This report studies the global Hypertensive Heart Disease Drug demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Hypertensive Heart Disease Drug, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2021 as the base year. This report explores demand trends and competition, as well as details the characteristics of Hypertensive Heart Disease Drug that contribute to its increasing demand across many markets.

The global Hypertensive Heart Disease Drug market size is expected to reach \$ million by 2028, rising at a market growth of % CAGR during the forecast period (2022-2028).

Highlights and key features of the study

Global Hypertensive Heart Disease Drug total market, 2017-2028, (USD Million)

Global Hypertensive Heart Disease Drug total market by region & country, CAGR, 2017-2028, (USD Million)

U.S. VS China: Hypertensive Heart Disease Drug total market, key domestic companies and share, (USD Million)

Global Hypertensive Heart Disease Drug revenue by player and market share 2017-2022, (USD Million)

Global Hypertensive Heart Disease Drug total market by Type, CAGR, 2017-2028,

(USD Million)

Global Hypertensive Heart Disease Drug total market by Application, CAGR, 2017-2028, (USD Million)

This reports profiles major players in the global Hypertensive Heart Disease Drug market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abbott Laboratories, AstraZeneca PLC, Actelion Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, Bayer AG, Eiger Biopharmaceuticals, Inc., Daiichi Sankyo Co., Ltd., Gilead Sciences, Inc. and GlaxoSmithKline PLC, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Hypertensive Heart Disease Drug market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2017-2028 by year with 2021 as the base year, 2022 as the estimate year, and 2028 as the forecast year.

Global Hypertensive Heart Disease Drug Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Hypertensive Heart Disease Drug Market, Segmentation by Type

Calcium Channel Blockers

Diuretics

Beta Blockers

ACE Inhibitors

Potassium Replacements

Global Hypertensive Heart Disease Drug Market, Segmentation by Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Companies Profiled:

Abbott Laboratories

AstraZeneca PLC

Actelion Pharmaceuticals Ltd.

Boehringer Ingelheim International GmbH

Bayer AG

Eiger Biopharmaceuticals, Inc.

Daiichi Sankyo Co., Ltd.

Gilead Sciences, Inc.

GlaxoSmithKline PLC

F. Hoffmann-La Roche Ltd.

Johnson & Johnson Services, Inc.

Lupin Pharmaceuticals, 13. Merck KGaA

Novartis AG

Pfizer Inc.

Sanofi SA

Sun Pharmaceutical Industries Ltd.

Takeda Pharmaceutical Co. Ltd.

United Therapeutics Corp.

Northern Therapeutics Inc.

Key Questions Answered

1. How big is the global Hypertensive Heart Disease Drug market?
2. What is the demand of the global Hypertensive Heart Disease Drug market?
3. What is the year over year growth of the global Hypertensive Heart Disease Drug market?

4. What is the total value of the global Hypertensive Heart Disease Drug market?
5. Who are the major players in the global Hypertensive Heart Disease Drug market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 Hypertensive Heart Disease Drug Introduction
- 1.2 World Hypertensive Heart Disease Drug Market Size & Forecast (2017 & 2021 & 2028)
- 1.3 World Hypertensive Heart Disease Drug Total Market by Region
 - 1.3.1 World Hypertensive Heart Disease Drug Market Size by Region (2017-2028)
 - 1.3.2 United States Hypertensive Heart Disease Drug Market Size (2017-2028)
 - 1.3.3 China Hypertensive Heart Disease Drug Market Size (2017-2028)
 - 1.3.4 Europe Hypertensive Heart Disease Drug Market Size (2017-2028)
 - 1.3.5 Japan Hypertensive Heart Disease Drug Market Size (2017-2028)
 - 1.3.6 South Korea Hypertensive Heart Disease Drug Market Size (2017-2028)
 - 1.3.7 ASEAN Hypertensive Heart Disease Drug Market Size (2017-2028)
 - 1.3.8 India Hypertensive Heart Disease Drug Market Size (2017-2028)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Hypertensive Heart Disease Drug Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Hypertensive Heart Disease Drug Major Market Trends
- 1.5 Influence of COVID-19 and Russia-Ukraine War
 - 1.5.1 Influence of COVID-19
 - 1.5.2 Influence of Russia-Ukraine War

2 WORLD HYPERTENSIVE HEART DISEASE DRUG COMPANIES COMPETITIVE ANALYSIS

- 2.1 World Hypertensive Heart Disease Drug Revenue by Player (2017-2022)
- 2.2 Industry Rank and Concentration Rate (CR)
 - 2.2.1 Global Hypertensive Heart Disease Drug Industry Rank of Major Players
 - 2.2.2 Global Concentration Ratios (CR4) for Hypertensive Heart Disease Drug in 2021
 - 2.2.3 Global Concentration Ratios (CR8) for Hypertensive Heart Disease Drug in 2021
- 2.3 Hypertensive Heart Disease Drug Company Evaluation Quadrant
- 2.4 Hypertensive Heart Disease Drug Market: Overall Company Footprint Analysis
 - 2.4.1 Hypertensive Heart Disease Drug Market: Region Footprint
 - 2.4.2 Hypertensive Heart Disease Drug Market: Company Product Type Footprint
 - 2.4.3 Hypertensive Heart Disease Drug Market: Company Product Application Footprint
- 2.5 Competitive Environment

- 2.5.1 Historical Structure of the Industry
- 2.5.2 Barriers of Market Entry
- 2.5.3 Factors of Competition
- 2.6 Mergers, Acquisitions Activity

3 UNITED STATES VS CHINA VS REST OF THE WORLD

- 3.1 United States VS China: Hypertensive Heart Disease Drug Market Comparison
 - 3.1.1 United States VS China: Hypertensive Heart Disease Drug Market Size Comparison (2017 & 2021 & 2028)
 - 3.1.2 United States VS China: Hypertensive Heart Disease Drug Market Size Market Share Comparison (2017 & 2021 & 2028)
- 3.2 United States Hypertensive Heart Disease Drug Major Players and Market Share, 2017-2022
 - 3.2.1 Major Players of Hypertensive Heart Disease Drug in United States, Headquarters (States, Country)
 - 3.2.2 United States Hypertensive Heart Disease Drug Revenue by Domestic Player, (2017-2022)
- 3.3 China Hypertensive Heart Disease Drug Major Players and Market Share, 2017-2022
 - 3.3.1 Major Players of Hypertensive Heart Disease Drug in China, Headquarters (Province, Country)
 - 3.3.2 China Hypertensive Heart Disease Drug Revenue by Domestic Player, (2017-2022)
- 3.4 Rest of World Hypertensive Heart Disease Drug Major Players and Market Share, 2017-2022
 - 3.4.1 Major Players of Hypertensive Heart Disease Drug in Rest of World, Headquarters (State, Country)
 - 3.4.2 Rest of World Hypertensive Heart Disease Drug Revenue by Domestic Player, (2017-2022)

4 MARKET ANALYSIS BY TYPE

- 4.1 World Hypertensive Heart Disease Drug Market Size Overview by Type: 2017 VS 2021 VS 2028
- 4.2 Segment Introduction by Type
 - 4.2.1 Calcium Channel Blockers
 - 4.2.2 Diuretics
 - 4.2.3 Beta Blockers

- 4.2.4 ACE Inhibitors
- 4.2.5 Potassium Replacements
- 4.3 Market Segment by Type
 - 4.3.1 World Hypertensive Heart Disease Drug Market Size by Type (2017-2022)
 - 4.3.2 World Hypertensive Heart Disease Drug Market Size by Type (2023-2028)
 - 4.3.3 World Hypertensive Heart Disease Drug Market Size Market Share by Type (2017-2028)

5 MARKET ANALYSIS BY APPLICATION

- 5.1 World Hypertensive Heart Disease Drug Market Size Overview by Application: 2017 VS 2021 VS 2028
- 5.2 Segment Introduction by Application
 - 5.2.1 Hospital Pharmacies
 - 5.2.2 Retail Pharmacies
 - 5.2.3 Online Pharmacies
- 5.3 Market Segment by Application
 - 5.3.1 World Hypertensive Heart Disease Drug Market Size by Application (2017-2022)
 - 5.3.2 World Hypertensive Heart Disease Drug Market Size by Application (2023-2028)
 - 5.3.3 World Hypertensive Heart Disease Drug Market Size by Application (2017-2028)

6 COMPANY PROFILES

- 6.1 Abbott Laboratories
 - 6.1.1 Abbott Laboratories Details
 - 6.1.2 Abbott Laboratories Major Business
 - 6.1.3 Abbott Laboratories Hypertensive Heart Disease Drug Product and Services
 - 6.1.4 Abbott Laboratories Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022)
 - 6.1.5 Abbott Laboratories Recent Developments/Updates
 - 6.1.6 Abbott Laboratories Competitive Strengths & Weaknesses
- 6.2 AstraZeneca PLC
 - 6.2.1 AstraZeneca PLC Details
 - 6.2.2 AstraZeneca PLC Major Business
 - 6.2.3 AstraZeneca PLC Hypertensive Heart Disease Drug Product and Services
 - 6.2.4 AstraZeneca PLC Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022)
 - 6.2.5 AstraZeneca PLC Recent Developments/Updates
 - 6.2.6 AstraZeneca PLC Competitive Strengths & Weaknesses

6.3 Actelion Pharmaceuticals Ltd.

6.3.1 Actelion Pharmaceuticals Ltd. Details

6.3.2 Actelion Pharmaceuticals Ltd. Major Business

6.3.3 Actelion Pharmaceuticals Ltd. Hypertensive Heart Disease Drug Product and Services

6.3.4 Actelion Pharmaceuticals Ltd. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022)

6.3.5 Actelion Pharmaceuticals Ltd. Recent Developments/Updates

6.3.6 Actelion Pharmaceuticals Ltd. Competitive Strengths & Weaknesses

6.4 Boehringer Ingelheim International GmbH

6.4.1 Boehringer Ingelheim International GmbH Details

6.4.2 Boehringer Ingelheim International GmbH Major Business

6.4.3 Boehringer Ingelheim International GmbH Hypertensive Heart Disease Drug Product and Services

6.4.4 Boehringer Ingelheim International GmbH Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022)

6.4.5 Boehringer Ingelheim International GmbH Recent Developments/Updates

6.4.6 Boehringer Ingelheim International GmbH Competitive Strengths & Weaknesses

6.5 Bayer AG

6.5.1 Bayer AG Details

6.5.2 Bayer AG Major Business

6.5.3 Bayer AG Hypertensive Heart Disease Drug Product and Services

6.5.4 Bayer AG Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022)

6.5.5 Bayer AG Recent Developments/Updates

6.5.6 Bayer AG Competitive Strengths & Weaknesses

6.6 Eiger Biopharmaceuticals, Inc.

6.6.1 Eiger Biopharmaceuticals, Inc. Details

6.6.2 Eiger Biopharmaceuticals, Inc. Major Business

6.6.3 Eiger Biopharmaceuticals, Inc. Hypertensive Heart Disease Drug Product and Services

6.6.4 Eiger Biopharmaceuticals, Inc. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022)

6.6.5 Eiger Biopharmaceuticals, Inc. Recent Developments/Updates

6.6.6 Eiger Biopharmaceuticals, Inc. Competitive Strengths & Weaknesses

6.7 Daiichi Sankyo Co., Ltd.

6.7.1 Daiichi Sankyo Co., Ltd. Details

6.7.2 Daiichi Sankyo Co., Ltd. Major Business

6.7.3 Daiichi Sankyo Co., Ltd. Hypertensive Heart Disease Drug Product and Services

6.7.4 Daiichi Sankyo Co., Ltd. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022)

6.7.5 Daiichi Sankyo Co., Ltd. Recent Developments/Updates

6.7.6 Daiichi Sankyo Co., Ltd. Competitive Strengths & Weaknesses

6.8 Gilead Sciences, Inc.

6.8.1 Gilead Sciences, Inc. Details

6.8.2 Gilead Sciences, Inc. Major Business

6.8.3 Gilead Sciences, Inc. Hypertensive Heart Disease Drug Product and Services

6.8.4 Gilead Sciences, Inc. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022)

6.8.5 Gilead Sciences, Inc. Recent Developments/Updates

6.8.6 Gilead Sciences, Inc. Competitive Strengths & Weaknesses

6.9 GlaxoSmithKline PLC

6.9.1 GlaxoSmithKline PLC Details

6.9.2 GlaxoSmithKline PLC Major Business

6.9.3 GlaxoSmithKline PLC Hypertensive Heart Disease Drug Product and Services

6.9.4 GlaxoSmithKline PLC Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022)

6.9.5 GlaxoSmithKline PLC Recent Developments/Updates

6.9.6 GlaxoSmithKline PLC Competitive Strengths & Weaknesses

6.10 F. Hoffmann-La Roche Ltd.

6.10.1 F. Hoffmann-La Roche Ltd. Details

6.10.2 F. Hoffmann-La Roche Ltd. Major Business

6.10.3 F. Hoffmann-La Roche Ltd. Hypertensive Heart Disease Drug Product and Services

6.10.4 F. Hoffmann-La Roche Ltd. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022)

6.10.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates

6.10.6 F. Hoffmann-La Roche Ltd. Competitive Strengths & Weaknesses

6.11 Johnson & Johnson Services, Inc.

6.11.1 Johnson & Johnson Services, Inc. Details

6.11.2 Johnson & Johnson Services, Inc. Major Business

6.11.3 Johnson & Johnson Services, Inc. Hypertensive Heart Disease Drug Product and Services

6.11.4 Johnson & Johnson Services, Inc. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022)

6.11.5 Johnson & Johnson Services, Inc. Recent Developments/Updates

6.11.6 Johnson & Johnson Services, Inc. Competitive Strengths & Weaknesses

6.12 Lupin Pharmaceuticals, 13. Merck KGaA

- 6.12.1 Lupin Pharmaceuticals, 13. Merck KGaA Details
- 6.12.2 Lupin Pharmaceuticals, 13. Merck KGaA Major Business
- 6.12.3 Lupin Pharmaceuticals, 13. Merck KGaA Hypertensive Heart Disease Drug Product and Services
- 6.12.4 Lupin Pharmaceuticals, 13. Merck KGaA Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022)
- 6.12.5 Lupin Pharmaceuticals, 13. Merck KGaA Recent Developments/Updates
- 6.12.6 Lupin Pharmaceuticals, 13. Merck KGaA Competitive Strengths & Weaknesses
- 6.13 Novartis AG
 - 6.13.1 Novartis AG Details
 - 6.13.2 Novartis AG Major Business
 - 6.13.3 Novartis AG Hypertensive Heart Disease Drug Product and Services
 - 6.13.4 Novartis AG Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022)
 - 6.13.5 Novartis AG Recent Developments/Updates
 - 6.13.6 Novartis AG Competitive Strengths & Weaknesses
- 6.14 Pfizer Inc.
 - 6.14.1 Pfizer Inc. Details
 - 6.14.2 Pfizer Inc. Major Business
 - 6.14.3 Pfizer Inc. Hypertensive Heart Disease Drug Product and Services
 - 6.14.4 Pfizer Inc. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022)
 - 6.14.5 Pfizer Inc. Recent Developments/Updates
 - 6.14.6 Pfizer Inc. Competitive Strengths & Weaknesses
- 6.15 Sanofi SA
 - 6.15.1 Sanofi SA Details
 - 6.15.2 Sanofi SA Major Business
 - 6.15.3 Sanofi SA Hypertensive Heart Disease Drug Product and Services
 - 6.15.4 Sanofi SA Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022)
 - 6.15.5 Sanofi SA Recent Developments/Updates
 - 6.15.6 Sanofi SA Competitive Strengths & Weaknesses
- 6.16 Sun Pharmaceutical Industries Ltd.
 - 6.16.1 Sun Pharmaceutical Industries Ltd. Details
 - 6.16.2 Sun Pharmaceutical Industries Ltd. Major Business
 - 6.16.3 Sun Pharmaceutical Industries Ltd. Hypertensive Heart Disease Drug Product and Services
 - 6.16.4 Sun Pharmaceutical Industries Ltd. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022)

- 6.16.5 Sun Pharmaceutical Industries Ltd. Recent Developments/Updates
- 6.16.6 Sun Pharmaceutical Industries Ltd. Competitive Strengths & Weaknesses
- 6.17 Takeda Pharmaceutical Co. Ltd.
 - 6.17.1 Takeda Pharmaceutical Co. Ltd. Details
 - 6.17.2 Takeda Pharmaceutical Co. Ltd. Major Business
 - 6.17.3 Takeda Pharmaceutical Co. Ltd. Hypertensive Heart Disease Drug Product and Services
 - 6.17.4 Takeda Pharmaceutical Co. Ltd. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022)
 - 6.17.5 Takeda Pharmaceutical Co. Ltd. Recent Developments/Updates
 - 6.17.6 Takeda Pharmaceutical Co. Ltd. Competitive Strengths & Weaknesses
- 6.18 United Therapeutics Corp.
 - 6.18.1 United Therapeutics Corp. Details
 - 6.18.2 United Therapeutics Corp. Major Business
 - 6.18.3 United Therapeutics Corp. Hypertensive Heart Disease Drug Product and Services
 - 6.18.4 United Therapeutics Corp. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022)
 - 6.18.5 United Therapeutics Corp. Recent Developments/Updates
 - 6.18.6 United Therapeutics Corp. Competitive Strengths & Weaknesses
- 6.19 Northern Therapeutics Inc.
 - 6.19.1 Northern Therapeutics Inc. Details
 - 6.19.2 Northern Therapeutics Inc. Major Business
 - 6.19.3 Northern Therapeutics Inc. Hypertensive Heart Disease Drug Product and Services
 - 6.19.4 Northern Therapeutics Inc. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022)
 - 6.19.5 Northern Therapeutics Inc. Recent Developments/Updates
 - 6.19.6 Northern Therapeutics Inc. Competitive Strengths & Weaknesses

7 RAW MATERIAL AND INDUSTRY CHAIN

- 7.1 Raw Material of Hypertensive Heart Disease Drug and Key Manufacturers
- 7.2 Hypertensive Heart Disease Drug Manufacturing Costs
- 7.3 Hypertensive Heart Disease Drug Production Process
- 7.4 Hypertensive Heart Disease Drug Industrial Chain

8 DISTRIBUTION CHANNEL ANALYSIS

8.1 Distribution Channel Breakdown for Hypertensive Heart Disease Drug Shipments (%) : 2017-2028

8.1.1 Direct Channel

8.1.2 Indirect Channel

8.2 Hypertensive Heart Disease Drug Typical Distributors

8.3 Hypertensive Heart Disease Drug Typical Customers

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

10.1 Methodology

10.2 Research Process and Data Source

10.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Hypertensive Heart Disease Drug Market Size by Region (2017, 2022 and 2028) & (USD Million)

Table 2. World Hypertensive Heart Disease Drug Market Size by Region (2017-2022) & (USD Million)

Table 3. World Hypertensive Heart Disease Drug Market Size by Region (2023-2028) & (USD Million)

Table 4. World Hypertensive Heart Disease Drug Market Size Market Share by Region (2017-2022)

Table 5. World Hypertensive Heart Disease Drug Market Size Market Share by Region (2023-2028)

Table 6. Major Market Trends

Table 7. World Hypertensive Heart Disease Drug Revenue by Player (2017-2022) & (USD Million)

Table 8. Revenue Market Share of Key Hypertensive Heart Disease Drug Players in 2021

Table 9. World Hypertensive Heart Disease Drug Industry Rank of Major Player, Based on Revenue in 2021

Table 10. Global Hypertensive Heart Disease Drug Company Evaluation Quadrant

Table 11. Head Office of Key Hypertensive Heart Disease Drug Player

Table 12. Hypertensive Heart Disease Drug Market: Company Product Type Footprint

Table 13. Hypertensive Heart Disease Drug Market: Company Product Application Footprint

Table 14. Hypertensive Heart Disease Drug Mergers & Acquisitions Activity

Table 15. United States VS China Hypertensive Heart Disease Drug Market Size Comparison, (2017 & 2021 & 2028) & (USD Million)

Table 16. Major Player of Hypertensive Heart Disease Drug in United States, Headquarters (States, Country)

Table 17. United States Hypertensive Heart Disease Drug Revenue by Domestic Player, (2017-2022) & (USD Million)

Table 18. United States Hypertensive Heart Disease Drug Revenue Market Share by Domestic Player, (2017-2022)

Table 19. Major Player of Hypertensive Heart Disease Drug in China, Company Headquarters (Province, Country)

Table 20. China Hypertensive Heart Disease Drug Revenue by Domestic Player, (2017-2022) & (USD Million)

Table 21. China Hypertensive Heart Disease Drug Revenue Market Share by Domestic Player, (2017-2022)

Table 22. Major Player of Hypertensive Heart Disease Drug in Rest of World, Company Headquarters (State, Country)

Table 23. Rest of World Hypertensive Heart Disease Drug Revenue by Domestic Player, (2017-2022) & (USD Million)

Table 24. Rest of World Hypertensive Heart Disease Drug Revenue Market Share by Domestic Player, (2017-2022)

Table 25. World Hypertensive Heart Disease Drug Revenue by Type, (USD Million), 2017 & 2021 & 2028

Table 26. World Hypertensive Heart Disease Drug Revenue by Type (2017-2022) & (USD Million)

Table 27. World Hypertensive Heart Disease Drug Revenue by Type (2023-2028) & (USD Million)

Table 28. World Hypertensive Heart Disease Drug Revenue by Application, (USD Million), 2017 & 2021 & 2028

Table 29. World Hypertensive Heart Disease Drug Revenue by Application (2017-2022) & (USD Million)

Table 30. World Hypertensive Heart Disease Drug Revenue by Application (2023-2028) & (USD Million)

Table 31. Abbott Laboratories Basic Information, Area Served and Competitors

Table 32. Abbott Laboratories Major Business

Table 33. Abbott Laboratories Hypertensive Heart Disease Drug Product and Services

Table 34. Abbott Laboratories Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 35. Abbott Laboratories Recent Developments/Updates

Table 36. Abbott Laboratories Competitive Strengths & Weaknesses

Table 37. AstraZeneca PLC Basic Information, Area Served and Competitors

Table 38. AstraZeneca PLC Major Business

Table 39. AstraZeneca PLC Hypertensive Heart Disease Drug Product and Services

Table 40. AstraZeneca PLC Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 41. AstraZeneca PLC Recent Developments/Updates

Table 42. AstraZeneca PLC Competitive Strengths & Weaknesses

Table 43. Actelion Pharmaceuticals Ltd. Basic Information, Area Served and Competitors

Table 44. Actelion Pharmaceuticals Ltd. Major Business

Table 45. Actelion Pharmaceuticals Ltd. Hypertensive Heart Disease Drug Product and Services

Table 46. Actelion Pharmaceuticals Ltd. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 47. Actelion Pharmaceuticals Ltd. Recent Developments/Updates

Table 48. Actelion Pharmaceuticals Ltd. Competitive Strengths & Weaknesses

Table 49. Boehringer Ingelheim International GmbH Basic Information, Area Served and Competitors

Table 50. Boehringer Ingelheim International GmbH Major Business

Table 51. Boehringer Ingelheim International GmbH Hypertensive Heart Disease Drug Product and Services

Table 52. Boehringer Ingelheim International GmbH Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 53. Boehringer Ingelheim International GmbH Recent Developments/Updates

Table 54. Boehringer Ingelheim International GmbH Competitive Strengths & Weaknesses

Table 55. Bayer AG Basic Information, Area Served and Competitors

Table 56. Bayer AG Major Business

Table 57. Bayer AG Hypertensive Heart Disease Drug Product and Services

Table 58. Bayer AG Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 59. Bayer AG Recent Developments/Updates

Table 60. Bayer AG Competitive Strengths & Weaknesses

Table 61. Eiger Biopharmaceuticals, Inc. Basic Information, Area Served and Competitors

Table 62. Eiger Biopharmaceuticals, Inc. Major Business

Table 63. Eiger Biopharmaceuticals, Inc. Hypertensive Heart Disease Drug Product and Services

Table 64. Eiger Biopharmaceuticals, Inc. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 65. Eiger Biopharmaceuticals, Inc. Recent Developments/Updates

Table 66. Eiger Biopharmaceuticals, Inc. Competitive Strengths & Weaknesses

Table 67. Daiichi Sankyo Co., Ltd. Basic Information, Area Served and Competitors

Table 68. Daiichi Sankyo Co., Ltd. Major Business

Table 69. Daiichi Sankyo Co., Ltd. Hypertensive Heart Disease Drug Product and Services

Table 70. Daiichi Sankyo Co., Ltd. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 71. Daiichi Sankyo Co., Ltd. Recent Developments/Updates

Table 72. Daiichi Sankyo Co., Ltd. Competitive Strengths & Weaknesses

Table 73. Gilead Sciences, Inc. Basic Information, Area Served and Competitors

Table 74. Gilead Sciences, Inc. Major Business

Table 75. Gilead Sciences, Inc. Hypertensive Heart Disease Drug Product and Services

Table 76. Gilead Sciences, Inc. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 77. Gilead Sciences, Inc. Recent Developments/Updates

Table 78. Gilead Sciences, Inc. Competitive Strengths & Weaknesses

Table 79. GlaxoSmithKline PLC Basic Information, Area Served and Competitors

Table 80. GlaxoSmithKline PLC Major Business

Table 81. GlaxoSmithKline PLC Hypertensive Heart Disease Drug Product and Services

Table 82. GlaxoSmithKline PLC Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 83. GlaxoSmithKline PLC Recent Developments/Updates

Table 84. GlaxoSmithKline PLC Competitive Strengths & Weaknesses

Table 85. F. Hoffmann-La Roche Ltd. Basic Information, Area Served and Competitors

Table 86. F. Hoffmann-La Roche Ltd. Major Business

Table 87. F. Hoffmann-La Roche Ltd. Hypertensive Heart Disease Drug Product and Services

Table 88. F. Hoffmann-La Roche Ltd. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 89. F. Hoffmann-La Roche Ltd. Recent Developments/Updates

Table 90. F. Hoffmann-La Roche Ltd. Competitive Strengths & Weaknesses

Table 91. Johnson & Johnson Services, Inc. Basic Information, Area Served and Competitors

Table 92. Johnson & Johnson Services, Inc. Major Business

Table 93. Johnson & Johnson Services, Inc. Hypertensive Heart Disease Drug Product and Services

Table 94. Johnson & Johnson Services, Inc. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 95. Johnson & Johnson Services, Inc. Recent Developments/Updates

Table 96. Johnson & Johnson Services, Inc. Competitive Strengths & Weaknesses

Table 97. Lupin Pharmaceuticals, 13. Merck KGaA Basic Information, Area Served and Competitors

Table 98. Lupin Pharmaceuticals, 13. Merck KGaA Major Business

Table 99. Lupin Pharmaceuticals, 13. Merck KGaA Hypertensive Heart Disease Drug Product and Services

Table 100. Lupin Pharmaceuticals, 13. Merck KGaA Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 101. Lupin Pharmaceuticals, 13. Merck KGaA Recent Developments/Updates

Table 102. Lupin Pharmaceuticals, 13. Merck KGaA Competitive Strengths & Weaknesses

Table 103. Novartis AG Basic Information, Area Served and Competitors

Table 104. Novartis AG Major Business

Table 105. Novartis AG Hypertensive Heart Disease Drug Product and Services

Table 106. Novartis AG Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 107. Novartis AG Recent Developments/Updates

Table 108. Novartis AG Competitive Strengths & Weaknesses

Table 109. Pfizer Inc. Basic Information, Area Served and Competitors

Table 110. Pfizer Inc. Major Business

Table 111. Pfizer Inc. Hypertensive Heart Disease Drug Product and Services

Table 112. Pfizer Inc. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 113. Pfizer Inc. Recent Developments/Updates

Table 114. Pfizer Inc. Competitive Strengths & Weaknesses

Table 115. Sanofi SA Basic Information, Area Served and Competitors

Table 116. Sanofi SA Major Business

Table 117. Sanofi SA Hypertensive Heart Disease Drug Product and Services

Table 118. Sanofi SA Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 119. Sanofi SA Recent Developments/Updates

Table 120. Sanofi SA Competitive Strengths & Weaknesses

Table 121. Sun Pharmaceutical Industries Ltd. Basic Information, Area Served and Competitors

Table 122. Sun Pharmaceutical Industries Ltd. Major Business

Table 123. Sun Pharmaceutical Industries Ltd. Hypertensive Heart Disease Drug Product and Services

Table 124. Sun Pharmaceutical Industries Ltd. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 125. Sun Pharmaceutical Industries Ltd. Recent Developments/Updates

Table 126. Sun Pharmaceutical Industries Ltd. Competitive Strengths & Weaknesses

Table 127. Takeda Pharmaceutical Co. Ltd. Basic Information, Area Served and Competitors

Table 128. Takeda Pharmaceutical Co. Ltd. Major Business

Table 129. Takeda Pharmaceutical Co. Ltd. Hypertensive Heart Disease Drug Product and Services

Table 130. Takeda Pharmaceutical Co. Ltd. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 131. Takeda Pharmaceutical Co. Ltd. Recent Developments/Updates
Table 132. Takeda Pharmaceutical Co. Ltd. Competitive Strengths & Weaknesses
Table 133. United Therapeutics Corp. Basic Information, Area Served and Competitors
Table 134. United Therapeutics Corp. Major Business
Table 135. United Therapeutics Corp. Hypertensive Heart Disease Drug Product and Services
Table 136. United Therapeutics Corp. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 137. United Therapeutics Corp. Recent Developments/Updates
Table 138. Northern Therapeutics Inc. Basic Information, Area Served and Competitors
Table 139. Northern Therapeutics Inc. Major Business
Table 140. Northern Therapeutics Inc. Hypertensive Heart Disease Drug Product and Services
Table 141. Northern Therapeutics Inc. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 142. Hypertensive Heart Disease Drug Raw Material
Table 143. Key Manufacturers of Hypertensive Heart Disease Drug Raw Materials
Table 144. Hypertensive Heart Disease Drug Typical Distributors
Table 145. Hypertensive Heart Disease Drug Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Hypertensive Heart Disease Drug Picture

Figure 2. World Hypertensive Heart Disease Drug Total Market Size: 2017 & 2021 & 2028, (USD Million)

Figure 3. World Hypertensive Heart Disease Drug Total Market Size (2017-2028) & (USD Million)

Figure 4. World Hypertensive Heart Disease Drug Market Size Market Share by Region (2017-2028)

Figure 5. United States Hypertensive Heart Disease Drug Market Size (2017-2028) & (USD Million)

Figure 6. China Hypertensive Heart Disease Drug Market Size (2017-2028) & (USD Million)

Figure 7. Europe Hypertensive Heart Disease Drug Market Size (2017-2028) & (USD Million)

Figure 8. Japan Hypertensive Heart Disease Drug Market Size (2017-2028) & (USD Million)

Figure 9. South Korea Hypertensive Heart Disease Drug Market Size (2017-2028) & (USD Million)

Figure 10. ASEAN Hypertensive Heart Disease Drug Market Size (2017-2028) & (USD Million)

Figure 11. India Hypertensive Heart Disease Drug Market Size (2017-2028) & (USD Million)

Figure 12. Hypertensive Heart Disease Drug Market Drivers

Figure 13. Factors Affecting Demand

Figure 14. Producer Shipments of Hypertensive Heart Disease Drug by Player Revenue (\$MM) and Market Share (%): 2021

Figure 15. Global Four-firm Concentration Ratios (CR4) for Hypertensive Heart Disease Drug Markets in 2021

Figure 16. Global Four-firm Concentration Ratios (CR8) for Hypertensive Heart Disease Drug Markets in 2021

Figure 17. United States VS China: Hypertensive Heart Disease Drug Market Size Market Share Comparison (2017 & 2021 & 2028)

Figure 18. World Hypertensive Heart Disease Drug Market Size by Type, (USD Million), 2017 & 2021 & 2028

Figure 19. World Hypertensive Heart Disease Drug Market Size Market Share by Type in 2021

Figure 20. Calcium Channel Blockers

Figure 21. Diuretics

Figure 22. Beta Blockers

Figure 23. ACE Inhibitors

Figure 24. Potassium Replacements

Figure 25. World Hypertensive Heart Disease Drug Market Size Market Share by Type (2017-2028)

Figure 26. World Hypertensive Heart Disease Drug Market Size by Application, (USD Million), 2017 & 2021 & 2028

Figure 27. World Hypertensive Heart Disease Drug Market Size Market Share by Application in 2021

Figure 28. Hospital Pharmacies

Figure 29. Retail Pharmacies

Figure 30. Online Pharmacies

Figure 31. World Hypertensive Heart Disease Drug Market Size Market Share by Application (2017-2028)

Figure 32. Manufacturing Cost Structure Analysis of Hypertensive Heart Disease Drug in 2021

Figure 33. Manufacturing Process Analysis of Hypertensive Heart Disease Drug

Figure 34. Hypertensive Heart Disease Drug Industrial Chain

Figure 35. Distribution Channel Breakdown for Hypertensive Heart Disease Drug Shipments (%): 2017-2028

Figure 36. Direct Channel Pros & Cons

Figure 37. Indirect Channel Pros & Cons

Figure 38. Methodology

Figure 39. Research Process and Data Source

I would like to order

Product name: Global Hypertensive Heart Disease Drug Production, Demand and Key Producers, 2022-2028

Product link: <https://marketpublishers.com/r/GB4F2E26189AEN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB4F2E26189AEN.html>